Graypoint LLC Sells 3,305 Shares of Kenvue Inc. (NYSE:KVUE)

Graypoint LLC decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 25.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,902 shares of the company’s stock after selling 3,305 shares during the period. Graypoint LLC’s holdings in Kenvue were worth $213,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. YHB Investment Advisors Inc. boosted its position in shares of Kenvue by 398.7% during the 4th quarter. YHB Investment Advisors Inc. now owns 75,730 shares of the company’s stock valued at $1,630,000 after purchasing an additional 60,543 shares in the last quarter. Ingalls & Snyder LLC raised its stake in Kenvue by 0.7% during the 4th quarter. Ingalls & Snyder LLC now owns 425,091 shares of the company’s stock worth $9,152,000 after buying an additional 2,839 shares during the period. ORG Partners LLC raised its stake in Kenvue by 1,611.4% during the 4th quarter. ORG Partners LLC now owns 3,149 shares of the company’s stock worth $68,000 after buying an additional 2,965 shares during the period. Deroy & Devereaux Private Investment Counsel Inc. raised its stake in Kenvue by 19.9% during the 4th quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 16,966 shares of the company’s stock worth $365,000 after buying an additional 2,812 shares during the period. Finally, Birch Hill Investment Advisors LLC raised its stake in Kenvue by 50.1% during the 4th quarter. Birch Hill Investment Advisors LLC now owns 167,071 shares of the company’s stock worth $3,597,000 after buying an additional 55,766 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. The Goldman Sachs Group assumed coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Sanford C. Bernstein assumed coverage on Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. JPMorgan Chase & Co. dropped their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Royal Bank of Canada lowered their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Finally, UBS Group increased their price objective on Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 19th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average target price of $24.85.

Kenvue Price Performance

Shares of KVUE opened at $19.13 on Tuesday. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. The stock has a 50 day moving average of $19.88 and a 200 day moving average of $20.18. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. Kenvue’s revenue was down 2.7% compared to the same quarter last year. As a group, analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Shareholders of record on Wednesday, February 14th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.18%. The ex-dividend date of this dividend was Tuesday, February 13th.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.